ROCKVILLE, Md.--(BUSINESS WIRE)--Celera (NYSE:CRA), an Applera Corporation business, has entered into a research collaboration with Merck & Co., Inc., to develop biomarker and pharmacogenomic tests for cancer patients. Under the terms of the agreement, Celera will evaluate the use of certain gene expression profiles identified by Merck with the goal of developing diagnostic predictors for use in Merck’s clinical trials, and to potentially form the basis for commercial companion diagnostic tests for oncology therapies.
